Chronic obstructive pulmonary disease (COPD) stands as the world's third leading cause of death, lacking a cure to date. Our pioneering efforts focus on developing a small molecule targeting a novel protein involved in the restoration of ciliated cells within COPD airways.

Easy & accurate long-term monitoring for Atrial Fibrillation. By providing unobtrusive, long-term monitoring and reliable diagnosis, Praxa Sense offers a solution to detect heart rhythm diseases in an early stage, preventing up to 9 strokes each day in The Netherlands alone.

We developed a test that accurately identifies patients that will develop rheumatoid arthritis within 3 years. Our mission is to substantially reduce the high burden of this disease by helping rheumatologists worldwide identify these high-risk patients in order to start preventive therapy.

PrecorDx develops a non-invasive diagnostic platform aimed at reducing hospital admissions and mortality in heart failure (19.5M patients in the USA and EU). This new diagnostic modality is based on the unique, novel Radio-Frequency Sensing (RFS) technology.

Predica’s mission is to personalize the population based screening program cervical cancer and thereby prevent overdiagnosis and unnecessary treatment of healthy women who test positive in the current screening program.

Prolira provides the first proprietary and validated biomarker-based medical device to detect the onset of delirium, with a sensitivity of 90%. This enables health care professionals in realising better patient outcome, saving hospital days and reducing costs.

Combating viral infectious diseases with a high unmet medical need. Treating disease via protease inhibition.

QurieGen provides quantitative information on the mode of action of drug molecules across multiple pathways over different timescales.

River BioMedics offers new human cardiac 3D models for target validation during drug discovery. Our 3D models are scalable to high-throughput and provide clinically relevant cardiac readouts for reliable drug efficacy validation.

CRISPR-Cas has revolutionized the field of gene editing and will also disrupt the field of molecular diagnostics. CRISPR diagnostics (CRISPR-Dx), combined with a pre-amplification step, are faster and easier than (q)PCR whilst obtaining results of the same quality.